NNVC — NANOVIRICIDES, INC.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1379006 ·
Last close
$1.16
Market Cap
$29.61M
52W High
$1.93
52W Low
$0.85
ADV30
178,270
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -5,768,489 | -5,742,936 | 9,562,717 | 2,575,227 | 3,150,427 |
| Jun 2026 | 0 | — | -2,246,284 | -2,223,399 | 9,873,614 | 2,794,110 | 1,190,724 |
| Mar 2026 | 0 | — | -2,030,218 | -1,989,333 | 10,219,004 | 3,213,256 | 1,065,407 |
| Dec 2025 | 0 | — | -2,233,174 | -2,220,719 | 12,267,640 | 5,150,580 | 1,195,925 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,276,000
Investing CF
$-94,516
Financing CF
$8,041,182
CapEx
$-94,517
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.44
As of
2026-10-05
Balance + Analyst (yfinance extras)
Retained Earnings
$-154,836,971
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-8,102,618
Pretax Income TTM
$-8,090,991
Interest Exp TTM
$0
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | -8,306,361 | -8,218,509 | 9,873,614 | 1,190,724 | 8,682,890 | -7,696,015 |
| Jun 2025 | 0 | -9,591,645 | -9,466,966 | 8,824,085 | 1,306,519 | 7,517,566 | -8,478,679 |
| Jun 2024 | 0 | -8,516,111 | -8,294,146 | 12,822,853 | 1,358,776 | 11,464,077 | -6,315,507 |
| Jun 2023 | 0 | -8,943,468 | -8,588,573 | 16,899,880 | 2,034,250 | 14,865,630 | -5,670,051 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-8,218,509
OpCashFlow TTM
—
Assets (Latest)
$10,219,004
Forward EPS
$-0.35
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRRUF | IMMUTEP Ltd | $29.47M | $0.02 | — |
| RLFTY | MindMaze Therapeutics Holding SA | $30.24M | $0.18 | — |
| AYTU | AYTU BIOPHARMA, INC | $28.91M | $2.66 | — |
| RDPTF | Radiopharm Theranostics Ltd | $28.89M | $0.01 | — |
| PMN | ProMIS Neurosciences Inc. | $28.88M | $3.21 | — |
News headlines (Yahoo Finance, 1h cache)
NanoViricides: Fiscal Q1 Earnings Snapshot
2026-11-17 14:13 · Yahoo
NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease,
2026-11-17 13:45 · Yahoo
An Investigational Drug to Tackle Measles Outbreaks
2026-11-10 13:45 · Yahoo
As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides
2026-10-27 13:15 · Yahoo
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way fo
2026-10-20 12:45 · Yahoo
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
2026-10-13 12:45 · Yahoo
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
2026-10-06 12:45 · Yahoo
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
2026-10-05 12:45 · Yahoo
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
2026-09-29 12:45 · Yahoo
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
2026-09-28 12:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.